Effect Of Entresto On Heart Failure After Emergency PCI In AMI Patients And Its Effect On Lp-PLA2

Objectives To investigate the effect of entresto on heart failure after emergency PCI in patients with AMI and its effect on Lp-PLA2.Methods From August 2020 to August 2021,120 patients with acute myocardial infarction(AMI)diagnosed and treated in Tangshan Workers’ Hospital with heart failure after emergency percutaneous coronary intervention(PCI)met the inclusion and exclusion criteria and were randomly divided into the experimental group or the control group.Both groups were given routine recommended drugs.Starting as early as possible after stable disease,the experimental group and the control group were treated with entresto and benazepril on the basis of routine treatment.Basic information was recorded after admission.After 6 months of treatment,n-terminal pro-b-type natriuretic peptide(NTpro BNP),creatinine(CREA),lipoprotein-associated phospholipase a2(Lp-PLA2)and cardiac color doppler ultrasound [left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD),left ventricular end diastolic volume(LVEDV),left ventricular short axis fractional shortening(FS),left ventricular ejection fraction(LVEF),interventricular septum end systolic thickness(IVSS),interventricular septum end diastolic thickness(IVSD),left ventricular end systolic posterior wall thickness(LVPWS),left ventricular end diastolic posterior wall thickness(LVPWD),left ventricular mass(LVM),left ventricular mass index(LVMI),left ventricular remodeling index(LVRI),left ventricular relative wall thickness(RWT)] were collected.The incidence of mace(cardiac death,recurrent myocardial infarction,angina,heart failure),and adverse reactions(elevated renal function index,hyperkalemia,neurovascular edema,hypotension)were recorded.Results 1 After treatment,NT-pro BNP and Lp-PLA2 in the experimental group were lower than those in the control group,and the decreased values of NT-pro BNP and LpPLA2 in the experimental group were higher than those in the control group(P<0.05).2 LVESD,LVEDD,LVEDV,LVM and LVMI in the experimental group were lower than those in the control group,LVEF and FS were higher than those in the control group,all of which were statistically different(P<0.05).There were no significant differences in IVSS,IVSD,LVPWS,LVPWD,LVRI,and RWT between the two groups(P>0.05).3 The decreased values of LVESD,LVEDD,LVEDV,LVM,LVMI and LVRI in the experimental group were higher than those in the control group,and the increased values of LVEF and FS were higher than those in the control group.There were significant differences in the above indexes and the change degree of RWT(P<0.05).There were no significant difference in the reduction of IVSS,IVSD,LVPWS,LVPWD(P>0.05).4 There was no significant difference between the two groups in the occurrence of cardiac death,recurrent myocardial infarction,angina,heart failure(P>0.05).However,the incidence of total mace in the two groups was 23.33%(11/60),35.00%(21/60),which was statistically different(P<0.05).5 No statistically significant differences were observed between the two groups in the incidence of adverse effects including elevated renal function index(5.00% vs 8.33%),hyperkalemia(3.33% vs 1.67%),neurovascular edema(0.00% vs 0.00%),and hypotension(6.67% vs 3.33%)(P>0.05).Conclusions 1 Compared with benazepril,entresto can significantly improve the cardiac function of heart failure after emergency PCI in patients with AMI,improve ventricular remodeling and reduce mace events,and has good safety.2 Compared with benazepril,entresto can significantly reduce Lp-PLA2,which is worthy of clinical promotion.Figure 14;Table 10;Reference 109...